|CANCER & TREATMENTS FOR CANCER CENTER PATIENTS PREVENTION & RISK ASSESSMENT CLINICAL TRIALS & RESEARCH LIVING WITH CANCER|
Please note: This article is part of the Cancer Center's News Archive and is here for historical purposes. The information and links may no longer be up-to-date.
Michigan Oncology Journal Fall 97
Cancer Center Dedicates Building<
Aging the Focus of Presidents Cancer Summit
U-M Physicians Listed Among Best Doctors for Women
Clinical TrialPhase I/II Study Evaluating the Safety and Biological Activity of Recombinant Vaccinia Prostate-Specific Antigen (Vaccinia-PSA) Vaccine in Patients with Serological Recurrence of Prostate Cancer Following Radical Prostatectomy
The purpose of this phase I/II trial is to study the effects of a PSA vaccine in men with prostate cancer that has recurred following radical prostatectomy. Patients will receive an injection of the vaccine followed by observation for two hours. Treatment may be repeated. Telephone follow-up will be on days 1, 3, and 5 after vaccine injection. Thereafter patients will have follow-up evaluations at the clinic. To be eligible, patients must have rising PSA levels, no chemotherapy, no flutamide for at least four to six weeks, no corticosteroids for at least 28 days, no metastases, no radiation therapy for at least 6 months and no radiation therapy to the head, not had the spleen removed, not had androgen ablation, no other cancer within the past five years except skin cancer, superficial bladder cancer, or in situ cancer other than of the urinary tract, received smallpox vaccine, no current or previous skin conditions, and no other serious medical problems. Patients must also have no close contact with children less than three years of age, pregnant women, or persons with skin conditions for at least two weeks after vaccination.
Darrell J. Fader, M.D.
John Wei, M.D.